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R E V I E W S  
M i " i f  ti ur ne coronavlrus n ec on: 
a paradigm for virus-induced 
demyelinating disease 
Thomas E. Lane and Michael J. Buchmeier 
C 
urrent hypotheses toex- 
plain the etiology and 
pathogenesis of demyel- 
inating diseases in humans in- 
clude the idea that an infectious 
agent encountered early in life 
may prime or trigger a disease 
process that manifests later in 
life as white-matter demyelin- 
ationL Although epidemiologi- 
cal evidence points to an infec- 
tious etiology, a single agent 
has never been linked convinc- 
ingly with human diseases such 
as multiple sclerosis (MS), a 
chronic central nervous ystem 
A variety of neurological diseases in 
humans, including multiple sderosis (MS), 
have been postulated to have a viral 
etiology. The use of animal models 
provides insights into potential 
mechanism(s) involved in the disease 
process. The murine coronavirus-induced 
demyelinating disease in rodents 
is one such model for demyelinating 
disease in humans. 
T.E. Lane and M.J. Buchmeier * are in the Dept of 
Neuropharmacology, The Scripps Research Institute, 
•0666 N. Torrey Pines Rd, La Jolla, CA 92037, 
USA. *tel: +1 619 784 7056, fax: +1 619 784 7369, 
e-mail: buchm@scripps.edu 
(CNS) disease that is characterized by multifocal in- 
flammatory loci and myelin destruction2,L Animal 
models of virus-induced demyelination have provided 
useful paradigms to study the demyelinating process. 
Coronaviruses constitute a large group of positive- 
stranded RNA viruses that are associated with a wide 
variety of respiratory, gastrointestinal and neurologi- 
cal diseases in animals and humans 4,s. Although the 
majority of coronavirus infections of humans are asso- 
ciated with upper respiratory tract infections, several 
laboratories have attempted tocorrelate inflammatory 
neurological disease with coronaviral infection, and re- 
cent reports have demonstrated the presence of corona- 
virus RNA and antigens in demyelinating plaque le- 
sions in the brains of MS patients 6,7. Furthermore, 
increased levels of antibodies against coronavirus have 
been detected in MS patients, as compared with con- 
trol patients s,and a murine coronavirus [mouse hepa- 
titis virus (MHV)], which had previously been thought 
only to infect mice, has recently been shown to replicate 
and cause demyelination i the CNS of nonhuman 
primates 9.At this time, however, there is no conclu- 
sive evidence that any human neurological disease, let 
alone MS, occurs as a result of human coronavirus in- 
fection. Certainly, other viruses, including herpes im- 
plex virus type-1 (HSV-1) 1°, measles 11and human T cell 
leukemia virus type i (HTLV-1) 12, have been suggested 
to be associated etiologically with MS (Ref. 13). How- 
ever, the accumulated ata suggest hat the human 
coronaviruses are capable of infecting both the human 
and nonhuman primate CNS. Given the existing ex- 
perimental evidence for murine coronavirus involve- 
ment in virus-induced CNS disease in rodents, the 
possibility that the human coro- 
naviruses are capable of causing 
a similar encephalomyelitis in 
humans remains open. Clearly, 
the results indicate that the host 
range and potential to cause dis- 
ease by coronaviruses are more 
complex than appreciated pre- 
viously and reinforce the need 
for a better understanding of the 
biology of human and mouse 
coronaviruses 9. 
The murine coronaviruses 
are capable of causing a vari- 
ety of diseases in mice, such as 
hepatitis and gastroenteritis 4. 
Infection of rodents with neuroadapted strains of 
MHV results in acute encephalitis and white-matter 
demyelination 4,5. There are several similarities be- 
tween MHV-induced demyelination and MS, which 
make this a good laboratory model for studying the 
underlying mechanisms of the MS disease process 
{Table 1 )14-161 (1) genetic susceptibility appears to play 
a prominent role in the development ofMS in humans 
while the genetic background of rodents, which de- 
termines usceptibility and immune response, isof cru- 
cial importance in MHV-induced emyelination3,14-17; 
(2) MS patients often experience cyclic periods of ex- 
acerbation followed by remission 3'18, and MHV-infected 
Table 1. Comparison of pathological events in multiple 
sclerosis (MS) and coronavirus demyelination 
Multiple sclerosis Coronavirus 
Infectious agent suggested by Viral trigger 
epidemiology 
Genetic susceptibility 
Multifocal white-matter lesions 
Exacerbation of disease 
symptoms 
Myelin stripping 
NOS-2 expression 
IFN- 7 
IL-1 
TNF-o~ 
Genetic susceptibility 
Multifocal white-matter lesions 
Subacute, acute and chronic 
stages 
Myelin stripping 
NOS-2 expression 
IFN-7 
IL-1 
TNF-c~ 
Abbreviations: IL-1, interleukin 1; IFN- 7, interferon 7; NOS-2, nitric oxide 
synthase; TNF-c(, tumor necrosis factor ~. 
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Fig. 1. Light micrograph showing a coronal section of spinal cord of mouse infected 32 days earlier 
with a demyelinating variant of mouse hepatitis virus (MHV). Two large foci of white-matter demyelin- 
ation are evident in the ventral funiculi and adjacent to the ventral median fissure. The section is 
stained with luxol fast blue. Scale bar = lO0#m. 
rodents go through progressive stages of subacute, acute 
and chronic disease accompanied by demyelination a d 
remyelination s,ls,~ s;and (3) in terms of neuropathology, 
MS patients and MHV-infected mice display multi- 
focal white-matter lesions accompanied by myelin strip- 
ping3,5,15,18-2°; in both cases, immune mechanisms are 
thought o participate in the disease. The cytokines 
TNF-(x (tumor necrosis factor 00, IFNq, (interferon 7) 
and IL-1 (interleukin 1 ), as well as the enzyme-inducible 
nitric oxide synthase (NOS-2), which is responsible for 
high-level output of the free radical nitric oxide (NO), 
have all been found to be localized to white matter 
plaques in humans with MS and MHV-infected mice 
experiencing demyelinating disease2>2% 
It should be emphasized that, in addition to the mu- 
rine coronavirus model of demyelination, there are a 
number of other excellent animal models for MS, such 
as the Theiler's murine encephalomyelitis virus (TMEV) 
system and the experimental llergic encephalomyelitis 
(EAE) model in mice and rats 27. This brief review will 
concentrate on the MHV/rodent system and its use as 
a model for human demyelinating disease. 
Background 
MHV is an enveloped virus containing a32-kb single- 
stranded RNA genome that replicates exclusively inthe 
cytoplasm of infected cells 2s. Virus replication occurs via 
a viral RNA-dependent RNA polymerase translated 
from open reading frame one of the genomic RNA. The 
three predominant s ructural proteins identified in MHV 
are the nucleocapsid protein (N; 60 kDa), which is as- 
sociated with the RNA genome, the membrane pro- 
tein (M; 25 kDa) and the spike pro- 
tein (S; 180 kDa) 8,2s. The S protein 
assembles into a trimeric peplomer, 
which exhibits a characteristic mor- 
phology described as a 'lollipop- 
like' spike, extending 20 nm from 
the surface of the virion 4. In ad- 
dition, a hemaglutinin-esterase pro- 
tein (HE; 65 kDa) is expressed by 
some strains of MHV (Refs 4,28). 
The S protein is an important 
determinant ofMHV biology and 
pathogenesis 4,5,14-16,2~,29. Functions 
associated with the S protein in- 
clude binding to host cell recep- 
tors, induction of fusion of viral 
envelope with cell membrane dur- 
ing entry, and induction of cell 
fusion (syncytium formation) 28. 
Williams et al. 3° have shown that 
the S protein recognizes a cellular 
receptor (MHV-R), which is a 
mouse biliary glycoprotein (BGP 
A) and a member of the murine 
carcinoembryonic antigen (CEA) 
family of glycoproteins. The 
MHV-R is found predominantly 
in the brush border of the small 
intestine and liver and is nearly un- 
detectable in the brain. Recently, 
Chen et al. ~ have reported a pregnancy-specific 
glycoprotein member of the CEA family, which is 
expressed in the brains of C57B1/6 mice and serves as 
a receptor for various strains of MHV. 
As with many viruses, the outcome of infection with 
MHV depends upon a variety of different factors, such 
as host and viral genetics and the dose and route of 
inoculation. For example, intranasal (i.n.) and intra- 
cranial (i.c.) infection of susceptible strains of mice, 
such as BALB/c and C57B1/6, with wild-type MHV 
(MHV-JHM) results in a rapid and fatal encephalo- 
myelitis that is accompanied by gray-matter involve- 
ment, with infection of neurons, oligodendrocytes and 
astrocytes and extensive damage to large areas of the 
olfactory and limbic system 14'15. The small percentage 
of mice that survive the initial bout of acute encepha- 
lomyelitis may develop a chronic demyelinating dis- 
ease that is characterized by extensive white-matter 
involvement and episodes of demyelination (Fig. 1) 14'15. 
The mice may also develop a hindlimb paralysis with 
some animals even developing tetraplegia. In contrast, 
infection of SJL/J mice with MHV-JHM does not re- 
sult in either an acute encephalitis or demyelination. 
The difference in genetic susceptibility between BALB/c 
and SJL/J to MHV-JHM is based on polymorphism 
in the BGP gene and is reflected in the sensitivity of 
neurons and macrophages to the virus 32,33. 
A number of different attentuated strains of MHV 
have been developed from the wild-type virus (MHV- 
JHM) through the use of either monoclonal antibodies 
raised against he S protein 29,:34, temperature-sensitive 
mutants 3s or long-term passage in cell culture 36. Mice 
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infected with these neuroattenuated strains generally do 
not develop fatal encephalitis but may develop neuro- 
logical disease that is characterized by mononuclear 
infiltration into the brain and spinal cord, as well as 
chronic demyelination 14-16,37" Neuroattentuated strains 
of MHV tend to spread very slowly through the CNS 
with little neuronal infection and the majority of in- 
fected cells being gila. It has been postulated that the 
slow rate of spread of certain neuroattenuated strains 
of MHV allows the intervention of the host immune 
response and, thus, the elimination of the bulk of in- 
fecting virus 37. 
Immune response and demyelination 
The immune response to MHV infection of the CNS 
plays a critical role in contributing to the pathogenesis 
of demyelination. Infection of Lewis rats with MHV- 
JHM results in the development of acute encephalo- 
myelitis and chronic demyelinating disease. At the 
onset of clinical symptoms, for example hindlimb 
paralysis, lymphocytes (both CD4+ and CD8 + T cells) 
enter the brain ~. However, when the animals conva- 
lesce, the number of infiltrating T cells drops to the levels 
seen before the occurrence of symptoms, suggesting 
that the T cells are participating in the disease process3L 
Gamma irradiation of MHV-infected mice results 
in higher titers of virus compared with non-irradiated 
control mice, but irradiated animals do not develop 
demyelination >. Adoptive transfer of MHV-immune 
splenocytes restores demyelination to the infected 
irradiated mice 39. Thy-1 + cells appear to be essential 
for the restoration of demyelination, indicating a role 
for T cells in the disease process. These data suggest 
that MHV-induced emyelination is immunologically 
mediated. 
A recent study by Houtman and Fleming 4° has used 
several strains of congenitally immunodeficient mice to 
discriminate between the role of the immune response 
in the clearance of infectious virus and in the develop- 
ment of demyelinating disease. Intracranial inoculation 
of a neuroattenuated MHV variant into immunocom- 
petent C57B1/6 mice results in clearance of infectious 
virus and robust demyelination. By contrast, virus- 
infected severe combined immunodeficient (SCID) mice 
did not clear the virus and did not develop demyelin- 
ation before dying 12 days postinfection. Demyelination 
with incomplete clearance of infectious virus was also 
observed in MHV-JHM-infected nude mice. Adoptive 
transfer of immune splenocytes from C57B1/6 mice, 
but not from nude mice, to SCID mice results in clear- 
ance of infectious virus and demyelination. 
These studies ubstantiate an immunological basis 
for demyelination i  MHV-infected mice and, further- 
more, suggest that elements of the immune system that 
are required for demyelination are distinct from those 
required for clearance of infectious virus. The fact that 
nude mice were unable to clear virus yet developed de- 
myelinating disease suggests that conventionally edu- 
cated T cells are not an essential component for de- 
myelination. The authors uggest that the 78 subset of 
T cells, natural killer cells, as well as cytokines, may 
participate in the demyelinating process 4°. 
It is also important to consider the major histocom- 
patibility complex (MHC) class I and II antigens in de- 
myelination following infection by MHV of resident 
cells of the CNS. Previous tudies involving MHV in- 
duction of MHC antigens on glial cells have been con- 
troversial. Infection of primary astrocytes results in an 
increase in class I expression, although this appears to 
be dependent upon both the MHV strain and the gen- 
etic background of the rodent414L Recent work by 
Gilmore et  al. 42 demonstrates that persistent infection 
of astrocytes by MHV results in an inhibition of class I
expression. Sun eta l .  2s report no expression of class I or 
II antigen by astrocytes inchronically infected mice ex- 
periencing demyelinating disease. Rather, inflamma- 
tory macrophage and microglia appear to be the pre- 
dominant cell type expressing these antigens 2s. The 
role of MHC class I in demyelination remains complex 
in light of recent reports indicating that demyelination 
can occur in MHV-infected mice that lack either stable 
expression of the MHC class I molecule 4°or functional 
CD8 ÷ T cells 44. 
Expression of MHC class II has been shown to be 
important in dictating the susceptibility of demyelin- 
ating disease to other animal models, such as TMEV 
(Ref. 45) and EAE (Ref. 46). Furthermore, infection 
of astrocytes from MHV-susceptible Lewis rats with 
MHV-JHM results in induction of MHC class II on 
the surface of the cell, whereas no similar increase was 
observed in astrocytes from disease-resistant Brown 
Norway rats 47'48. However, mice deficient in class II 
expression express robust demyelination following in- 
fection with MHV-JHM (Ref. 40). Therefore, it may 
be possible that other genes, in addition to, or distinct 
from, MHC class I and II, may control the outcome of 
demyelination. 
The question of whether MHV infection generates 
autoimmune T cells, which contribute to &myelin- 
ation, is controversial nd appears to depend on the 
system being studied. Recent work by Talbot et  al. 49 
has demonstrated the presence of T cells that are cross- 
reactive with myelin basic protein (MBP) and human 
coronavirus antigen from patients uffering from MS. 
Watanabe t  aL so have reported that MBP-specific T 
cells are generated in rats infected with MHV-JHM. 
Transfer of these cells to naive animals results in CNS 
inflammation but not significant demyelinating lesions. 
The potential for such an autoimmune r sponse against 
myelin epitopes in the MHV/mouse model must be 
considered sl.
MHV persistence and demyelination 
Recent reports have suggested that human corona- 
virus RNA may persist in the CNS in demyelinating 
lesions of patients with MS (Refs 6,7). MHV-infected 
mice develop chronic demyelinating disease, yet it is 
not always possible to isolate infectious virus from the 
CNS compartment. Thus, it is important to consider the 
nature of viral persistence in the MHWmouse model. 
Recent investigation ofthe evolution of MHV RNAs 
during persistence in the CNS has demonstrated that 
the genomic RNA rapidly evolves into a diverse popu- 
lation of mutant RNA quasi-species within the CNS. 
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Box 1. Potential mechanisms of demyelination induced 
by mouse hepatitis virus (MHV) 
Virus persistence 
• Disrupts oligodendrocyte function 
• In astrocytes, results in chronic NOS-2 (nitric oxide synthase), 
TN F-c~ (tumor necrosis factor (x) and IL-6 (interleukin 6) expression 
and glial toxicity 
• Persistent viral antigens expressed in glial cells target chronic 
immune response to white matter 
Molecular mimicry 
• Virus infection primes immune response to crossreact with myelin 
antigens, such as myelin basic protein (MBP) and proteolipid 
protein (PLP) 
Infectious virus can be isolated from mice suffering 
from demyelinating disease if the animals are infected 
at the suckling stage and nursed by immunized dams 5s,s6. 
An elegant study by Pewe et  al. -~7 demonstrates that 
virus persisting in the brain and spinal cords of mice 
suffering from chronic, but not acute, demyelinating 
disease undergoes changes within the hypervariable 
region of the S gene, which has previously been defined 
as a CD8* T-cell epitope. These data suggest that these 
viral variants escape from cytotoxic T lymphocyte 
(CTL) recognition, which then allows for enhanced 
viral replication within the CNS and the development 
of clinical disease 57. 
Adami et  al. s2 investigated coronaviral persistence by 
examining viral sequences from the brains of mice 
from 0-42 days postinfection with a neuroattenuated 
variant of MHV. Although infectious virus was not de- 
tected in the brain beyond 13 days postinfection, viral 
RNA was easily detected by reverse transcription- 
polymerase chain reaction (RT-PCR) amplification. Se- 
quence analysis of the cloned PCR products revealed 
that multiple point and deletion mutations had oc- 
curred, many of which were concentrated in both the S 
and N sequences. Greater than 65% of the nucleotide 
changes observed resulted in amino acid changes, ug- 
gesting that a strong selective pressure xists within the 
CNS. Many of the mutations and deletions reported in 
the S sequence were concentrated in the hypervariable 
domain, originally described by Parker et al. s3 and con- 
tinued by Banner and Lai 54. These findings uggest that 
a diverse population of RNA quasi-species, many of 
which are likely to be defective, persist within the CNS. 
The consequences of this type of infection may con- 
tribute to the pathogenesis of chronic demyelination 
by perturbing normal cellular function or, if the RNAs 
are translationally active, by chronically stimulating 
the immune system s3. 
Table 2. Host factors that may contribute to virus-induced 
demyelination 
Host factor Pathology 
TNF-(z 
IFN- 7 
IL-3 
IL-4 
IL-6 
NOS-2 
Recruitment of inflammatory cells to CNS 
Direct toxicity to oligodendrocytes 
Induction of neuronal apoptosis 
T-cell activation 
Induction of the major histocompatibility complex (MHC) and 
the receptor for the Fc domain of immunoglobulin 
Macrophage/microglial ctivation 
T-cell proliferation 
T-cell proliferation 
Enhancement of antibody response 
Direct toxicity to oligodendrocytes 
Nitric oxide production 
Toxicity to oligodendrocytes 
Abbreviations: CNS, central nervous system; IL-3, interleukin 3; IL-4, interleukin 4; IL-6, 
interleukin 6; IFN-y, interferon 7; TNF-(x, tumor necrosis factor (x; NOS-2, nitric oxide 
synthase. 
Mechanism(s) of chronic demyelinating disease 
A variety of different mechanisms have been postu- 
lated to contribute to MHV-induced isease (Box 1). 
As discussed above, the pathological basis for disease 
depends on a variety of factors, including the system 
being studied (i.e. mouse versus rat), the age and gen- 
etic background ofthe rodent and the dose and strain of 
virus being used. Direct lysis of oligodendrocytes (the 
cells responsible for myelin production and mainte- 
nance in the brain) by MHV during the acute phase of 
infection has been suggested tobe responsible for acute 
demyelinating lesions in the CNS (Refs 19,20,35). 
The mechanism(s) responsible for demyelination 
in chronically infected animals is less understood. Al- 
though MHV infects glia, such as astrocytes and oligo- 
dendrocytes, readily in v i t ro  and in  v ivo ,  recent work 
by Perlman and Reis s8 has shown that astrocytes are 
the cells that harbor the virus within the brains and 
spinal cords of infected animals uffering from chronic 
disease. Moreover, histological evidence suggests hat 
MHV-infected astrocytes are activated, as measured 
by increased staining for glial fibrillary acidic protein 
(GFAP) 2s. These observations are interesting because 
astrocytes are closely associated with oligodendrocytes 
and are required by the oligodendrocyte for normal 
cellular function. Therefore, any perturbation 
of astrocyte function and/or production of 
toxic factors, for example cytokines and NO, 
may have dramatic effects on the surround- 
ing microenvironment a d may contribute 
potentially to demyelination 25 (Table 2). 
Sun et  al. 25 have measured increased stain- 
ing for the cytokines TNF-ot, IL-1[3, and IL-6, 
as well as NOS-2, in the spinal cords of mice 
chronically infected with MHV and con- 
taining demyelinating lesions. Although as- 
sociated with areas of viral infection and 
demyelination, the activated astrocytes were 
generally not infected with virus. Both NO 
and TNF-ot have been shown to be toxic to 
oligodendrocytes s9-61. In the murine EAE 
model, inhibition of NOS-2 activity amelio- 
rates demyelination, suggesting a contribu- 
tory role for NO in the demyelinating pro- 
cess 62. Furthermore, r cent work by Boullerne 
et  al. 63 suggests hat NO may be involved in 
MS demyelination. Sun et  al. 25 speculate hat 
production of these factors may contribute 
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to the demyelinating process. However, there is some 
controversy as to the role TNF-¢~ has in the disease pro- 
cess; Stohlman et al. 64 have reported that administration 
of antibodies against TNF-ct does not ameliorate either 
MHV-induced encephalomyelitis or demyelination, 
suggesting that the production of TNF-ct alone is not 
central to the disease process. 
In addition to the role of T cells and cytokines in virus 
clearance and demyelination, our laboratory is focus- 
ing on the role played by chemokines in the demyelin- 
ating disease process. Chemokines function as chemo- 
attractants for specific populations of cells to sites of 
inflammation. Recent work has demonstrated a promi- 
nent role for the chemokines MIP (macrophage inflam- 
matory protein)-lo~, MIP-1IB and RANTES (regulated 
upon activation ormal T-expressed and presumably se- 
creted protein) during the acute phase of EAE (Refs 65, 
66). Furthermore, glial cells can produce chemokines 
and potentially contribute to the development of EAE 
and, possibly, other neurodegenerative diseases 65,66. It 
is interesting to speculate that chemokines may be con- 
tributing to MHV-induced demyelinating disease by 
attracting the effector cells, for example monocytes 
and/or T cells, to the brain and spinal cord, which may 
then participate in demyelination. 
Conclusions 
This brief review has focused on the use of the murine 
coronavirus as a model for human demyelinating dis- 
eases and has addressed several unresolved questions 
in the field of coronavirus-induced demyelination. We 
have touched on recent advances in the understand- 
ing of the mechanism(s) involved in MHV-induced 
demyelination in rodents. Although exciting epidemio- 
logical evidence suggests a viral etiology or cofactor 
in MS, direct evidence is elusive. With the advent of 
more-sensitive t chniques for virus detection, accom- 
panied by increasing advances in the understanding 
of the complex immunological mechanisms involved 
in CNS diseases, a better understanding of human de- 
myelinating diseases lies on the horizon. 
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Vacc" " " p lses" l na t lon  In  u . 
a strategy for global eradication 
of measles and polio? 
D. James Nokes and Jonathan Swinton 
T he global eradication of smallpox, declared in 1979 (Ref. 1), was hoped 
to be the first in a rapid se- 
quence of successes in the fight 
to control the major childhood 
infectious diseases by vacci- 
nation. In spite of major 
achievements in raising global 
vaccination coverage through 
routine infant immunization, 
today it is clear that infections 
such as measles, poliomyelitis 
and whooping cough are highly 
effective adversaries and con- 
tinue to exact a huge toll in 
death and disability, particu- 
larly in the developing world z,3. 
Recent American successes against 
poliomyelitis and measles have been 
attributed to repeated 'pulse' vaccination 
campaigns. Whilst logistic and economic 
constraints will be crucial, a deeper 
epidemiological understanding of the 
mechanism, strengths and weaknesses of 
pulse vaccination will optimize the chances 
of success elsewhere in the world. 
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In the light of greater understanding of their epi- 
demiology and the level of resources and health service 
infrastructure that are likely to be needed to interrupt 
transmission, a less-sanguine outlook on our chances 
of global eradication of these childhood scourges now 
exists. Theoretical study has identified a level of vac- 
cination coverage (achieving a 'herd immunity' thresh- 
old 4,s) above which persistence of infection would be 
unlikely. The threshold is agent and population spe- 
cific but generally falls around 80-95% of the popu- 
lation having vaccine-induced immunity 4. Smallpox 
was something of an outlier, with a predicted thresh- 
old of nearer 75 % (Ref. 6). Achieving these high levels 
of coverage represents a daunting task and, in the face 
of financial, political, motivational and communi- 
cation difficulties, may not be 
possible through routine pri- 
mary health services in many 
parts of the world. 
In this context, it is not sur- 
prising that the achievements of 
the past decade in Central and 
South America have become a
focus of attention. In 1994, the 
Americas were declared polio 
free; the last case recorded was 
in Peru in 1991 (Ref. 7). Further- 
more, throughout the Americas 
reports of measles are at an all- 
time low, with sights firmly set 
upon regional elimination with- 
in the next few years 8. Much 
of this success has been attrib- 
uted to the contribution of vaccination campaigns, re- 
peated at intervals, in which children of a wide age 
range are offered vaccine 9,1°. Such campaigns, it is 
reasoned, achieve their effect by rapidly starving the 
infectious disease of its supply of susceptible individ- 
uals 1°-12. In a single campaign, a large fraction of the 
pool of susceptibles in a population may be immunized. 
The effect is to decrease incidence drastically. In con- 
trast to this, routine infant immunization procedures 
only immunize part of each yearly birth cohort; the 
resultant impact on incidence is slower and less dra- 
matic. In theory, following a campaign or pulse of 
vaccine, there is no further need to vaccinate until the 
susceptible fraction has been restored through births 
to its original or epidemic threshold13-xq 
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